Showing 401 - 420 results of 2,774 for search 'Toteng~', query time: 3.16s Refine Results
  1. 401
  2. 402
  3. 403
  4. 404

    IL-2-armored peptide-major histocompatibility class I bispecific antibodies redirect antiviral effector memory CD8+ T cells to induce potent anti-cancer cytotoxic activity with limited cytokine release by John S. Schardt, Even Walseng, Kim Le, Chunning Yang, Pooja Shah, Ying Fu, Kausar Alam, Cathryn R. Kelton, Yu Gu, Fengying Huang, Jia Lin, Wenhai Liu, Andrew Dippel, Hanzhi Zhang, Kathy Mulgrew, Stacy Pryts, Vijaykumar Chennupati, Hung-Chang Chen, Jessica Denham, Xiaoru Chen, Pallab Pradhan, Yuling Wu, Colin Hardman, Chihao Zhao, Michael Kierny, Yang Song, Simon J. Dovedi, Saso Cemerski, Yariv Mazor

    Published 2024-12-01
    “…T cell engagers (TCEs) are becoming an integral class of biological therapeutic owing to their highly potent ability to eradicate cancer cells. Nevertheless, the widespread utility of classical CD3-targeted TCEs has been limited by narrow therapeutic index (TI) linked to systemic CD4+ T cell activation and aberrant cytokine release. …”
    Get full text
    Article
  5. 405

    Potency of Bone Marrow-Derived Mesenchymal Stem Cells and Indomethacin in Complete Freund’s Adjuvant-Induced Arthritic Rats: Roles of TNF-α, IL-10, iNOS, MMP-9, and TGF-β1 by Eman A. Ahmed, Osama M. Ahmed, Hanaa I. Fahim, Tarek M. Ali, Basem H. Elesawy, Mohamed B. Ashour

    Published 2021-01-01
    “…The combinatory effect of the two treatments was the most potent. In conclusion, the treatment of RA with BM-MSCs and IMC together is more effective than the treatment with either BM-MSCs or IMC. …”
    Get full text
    Article
  6. 406
  7. 407
  8. 408
  9. 409
  10. 410
  11. 411
  12. 412
  13. 413
  14. 414
  15. 415

    PD-L1/TLR7 dual-targeting nanobody-drug conjugate mediates potent tumor regression via elevating tumor immunogenicity in a host-expressed PD-L1 bias-dependent way by Wei Huang, Ji Zhou, Jia Li, Yakun Wan, Chao Hu, Meng Liu, Pan Xu, Feng Tang, Jianhua Sun, Xiaolu Yu, Yiru Long, Binfan Chen, Yongliang Tong, Mengwen Shan, Xiaomin Jia, Henglei Lu, Runqiu Chen, Jin Ren, Guangyi Jin, Likun Gong

    Published 2022-10-01
    “…Moreover, the efficacy of NDCs is biased toward dependence on host expression of PD-L1.Conclusions The novel PD-L1/TLR7 dual-targeting NDC exhibited potent efficacy against heterogeneous tumors through orchestrating innate and adaptive immunity, which could act as a promising strategy to improve ICB therapy and shows prospects for clinical development.…”
    Get full text
    Article
  16. 416
  17. 417
  18. 418
  19. 419
  20. 420